Physician profile
Dmitry Mysh
NPI 1033105903
$4,486.51
in general payments reported to CMS, 2019-2025
16 companies · $993 in 2025
The $993 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $528 · 2021: $519 · 2022: $760 · 2023: $680 · 2024: $865 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,697.39 | 2019-2025 | |
| Janssen Biotech, INC. | $625.06 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $484.94 | 2020-2025 | Exalt Model D, Advanix Biliary |
| Gilead Sciences, INC. | $201.57 | 2019-2020 | |
| Medtronic, INC. | $182.25 | 2023 | Endoflip |
| Exact Sciences Corporation | $181.51 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $155.07 | 2021-2022 | |
| Madrigal Pharmaceuticals | $139.79 | 2025 | Rezdiffra |
| Amgen INC. | $136.49 | 2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $136.37 | 2019-2023 | Gattex |
| Ipsen Biopharmaceuticals, INC | $128.35 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $124.97 | 2025 | Voquezna |
| Pfizer INC. | $108.16 | 2020 | |
| Daiichi Sankyo INC. | $101.52 | 2022 | |
| Stryker Corporation | $68.42 | 2023 | Stryker |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $14.65 | 2025 | Endoclot Phs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Mysh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.